Accordingly, combination efficacy extended to an in vivo setting of TH-MYCN+/+ mice with established tumors, where S63845 + barasertib outperformed the vehicle control or single agents in terms of tumor growth delay (Figure 6D). Here, MYCN is linked to neoplasm.